ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancerDavid Planchard, Dariusz M. Kowalski, Shunichi Sugawara et al.|Annals of Oncology|2020Cited by 164
ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatmentDariusz M. Kowalski, David Planchard, Niels Reinmuth et al.|Annals of Oncology|2018Cited by 17